Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation

Plasma amyloid-beta (Aβ) has long been investigated as a blood biomarker candidate for Cerebral Amyloid Angiopathy (CAA), however previous findings have been inconsistent which could be attributed to the use of less sensitive assays. This study investigates plasma Aβ alterations between pre-symptomatic Dutch-type hereditary CAA (D-CAA) mutation-carriers (MC) and non-carriers (NC) using two Aβ measurement platforms. Seventeen pre-symptomatic members of a D-CAA pedigree were assembled and followed up 3–4 years later (NC = 8; MC = 9). Plasma Aβ1-40 and Aβ1-42 were cross-sectionally and longitudin... Mehr ...

Verfasser: Pratishtha Chatterjee
Michelle Tegg
Steve Pedrini
Anne Fagan
Chengjie Xiong
Abhay Singh
Kevin Taddei
Samantha Gardener
Colin Masters
Peter Schofield
Gerhard Multhaup
Tammie Benzinger
John Morris
Randall Bateman
Steven Greenberg
Mark van Buchem
Erik Stoops
Hugo Vanderstichele
Charlotte Teunissen
Graeme Hankey
Marieke Wermer
Hamid Sohrabi
Ralph Martins
the Dominantly Inherited Alzheimer Network
Dokumenttyp: Text
Erscheinungsdatum: 2021
Verlag/Hrsg.: Multidisciplinary Digital Publishing Institute
Schlagwörter: amyloid-beta / plasma amyloid-beta / blood biomarkers / cerebral amyloid angiopathy / early diagnosis / hereditary cerebral haemorrhage with amyloidosis—Dutch type / single molecule array platform
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28996294
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.3390/ijms22062931

Plasma amyloid-beta (Aβ) has long been investigated as a blood biomarker candidate for Cerebral Amyloid Angiopathy (CAA), however previous findings have been inconsistent which could be attributed to the use of less sensitive assays. This study investigates plasma Aβ alterations between pre-symptomatic Dutch-type hereditary CAA (D-CAA) mutation-carriers (MC) and non-carriers (NC) using two Aβ measurement platforms. Seventeen pre-symptomatic members of a D-CAA pedigree were assembled and followed up 3–4 years later (NC = 8; MC = 9). Plasma Aβ1-40 and Aβ1-42 were cross-sectionally and longitudinally analysed at baseline (T1) and follow-up (T2) and were found to be lower in MCs compared to NCs, cross-sectionally after adjusting for covariates, at both T1(Aβ1-40: p = 0.001; Aβ1-42: p = 0.0004) and T2 (Aβ1-40: p = 0.001; Aβ1-42: p = 0.016) employing the Single Molecule Array (Simoa) platform, however no significant differences were observed using the xMAP platform. Further, pairwise longitudinal analyses of plasma Aβ1-40 revealed decreased levels in MCs using data from the Simoa platform (p = 0.041) and pairwise longitudinal analyses of plasma Aβ1-42 revealed decreased levels in MCs using data from the xMAP platform (p = 0.041). Findings from the Simoa platform suggest that plasma Aβ may add value to a panel of biomarkers for the diagnosis of pre-symptomatic CAA, however, further validation studies in larger sample sets are required.